Category Archives: Stem Cell Treatments

The global cancer stem cells market expected to grow by 2026 due to rising prevalence of cancer. The breast cancer sub-segment is expected to be highly profitable. Market in the North America region is expected to be highly lucrative.

NEW YORK, Aug. 19, 2022 /PRNewswire/ --Research Dive has added a new report to its offering titled, "Cancer Stem Cells Market, By Cancer Form (Breast, Blood, Lung, Brain, Colorectal, Pancreatic, Bladder, Liver), By Application (Targeted CSCs, Stem Cell Based Cancer Therapy): Global Opportunity Analysis and Industry Forecast, 20192026".

Research Dive Logo

According to the report, the global cancer stem cells market is expected to gather a revenue of $1,722.7 million by 2026, growing at a CAGR of 10.3% during the 2019-2026 timeframe.

Dynamics of the Cancer Stem Cells Market

Drivers: Increasing prevalence of cancer all across the globe is projected to be the primary growth driver of the cancer stem cells market in the forecast period. Additionally, the growth in awareness among people regarding cancer is expected to increase the growth rate of the market.

Opportunities: The extensive focus of various organizations and medical experts on developing new cancer treatments and improving the efficiency of the existing ones is predicted to offer huge growth opportunities to the market. Along with this, growth in the number of cancer patients all over the world is anticipated to push the market forward.

Restraints: Expensive cell therapy treatments may hamper the growth trajectory of the cancer stem cells market.

To get access to the Comprehensive PDF Sample [180-Pages] of Cancer Stem Cells Market Click here!

Segments of the Cancer Stem Cells Market

The report has divided the cancer stem cells market into a few segments based on cancer form, application, and regional analysis.

By cancer form, the breast cancer sub-segment of the cancer stem cells market is estimated to have a dominating share and garner $295.0 million by 2026. Changing lifestyle, hormonal changes, consumption of alcohol, etc. have led to an increase in prevalence of breast cancer in people worldwide, which is predicted to push the market forward.

By application, stem cell based cancer therapy sub-segment is anticipated to have a stunning growth rate and surpass $896.9 million by the end of 2026. Stem cell based cancer therapy comprises of allogenic stem cell therapy and autologous stem cell therapy, which are widely used for treating different types of cancers. This is expected to help the sub-segment grow in the forecast period.

By regional analysis, the cancer stem cells market in the North America region is predicted to flourish immensely and garner a revenue of $783.8 million by 2026. Medical experts and doctors in this region are quite involved in cancer related research and help in promotion of stem cell interventions, which is why the market is expected to grow at such a stunning rate in this region.

Story continues

Broader Insights Pertaining (Avail 10%OFF) of Specific Segments or Regions of Cancer Stem Cells Market

Significant Cancer Stem Cells Market Players

Some prominent market players of the cancer stem cells market are

AdnaGen GmbH

Epic Sciences, Inc.

Silicon Biosystems

S.p.A.

Advanced Cell Diagnostics, Inc.

Fluxion Biosciences, Inc.

AVIVA Biosciences Corporation

Rarecells USA, Inc.

Celula, Inc.

These players are developing various business strategies like product development and enhancement, merger and acquisition, partnerships and collaborations to gain a commanding position in the market. Buy the Full Report Here Started at $2999

For example, in January 2022, Century Therapeutics, a leading biotechnology company, announced a partnership with Bristol Myers Squibb, a multinational pharmaceutical company. The collaboration is aimed at developing four induced pluripotent stem cell derived programs in order to tackle malignant tumors. The partnership is expected to hugely benefit both the companies as they will be able to integrate their operations in a much better way in order to develop the intended program.

The report also sums up various crucial facets including SWOT analysis, product portfolio, financial performance of the key market players, and the latest strategic developments.

Checkout the Latest Insights of Cancer Stem Cells Market. Schedule a call with an Analyst

More about Cancer Stem Cells Market:

Some trending Article Links:

About Research Dive

Research Dive is a market research firm based inPune, India. Maintaining the integrity and authenticity of the services, the firm provides the services that are solely based on its exclusive data model, compelled by the 360-degree research methodology, which guarantees comprehensive and accurate analysis. With an unprecedented access to several paid data resources, team of expert researchers, and strict work ethic, the firm offers insights that are extremely precise and reliable. Scrutinizing relevant news releases, government publications, decades of trade data, and technical & white papers, Research dive deliver the required services to its clients well within the required timeframe. Its expertise is focused on examining niche markets, targeting its major driving factors, and spotting threatening hindrances. Complementarily, it also has a seamless collaboration with the major industry aficionado that further offers its research an edge.

Contact:

Mr.Abhishek PaliwalResearch Dive30 Wall St. 8th Floor,New York NY10005(P) +91-(788)-802-9103 (India)+1-(917)-444-1262 (US)Toll Free: 1-888-961-4454E-mail: support@researchdive.comWebsite:https://www.researchdive.comBlog:https://www.researchdive.com/blog/LinkedIn:https://www.linkedin.com/company/research-dive/Twitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-Dive-1385542314927521

Logo: https://mma.prnewswire.com/media/997523/Research_Dive_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/global-cancer-stem-cells-market-estimated-to-reach-1-722-7-million-by-2026-and-grow-at-10-3-cagr-in-the-2019-to-2026-timeframe--180-pages-report-by-research-dive-301608439.html

SOURCE Research Dive

Go here to see the original:
Global Cancer Stem Cells Market Estimated to Reach $1,722.7 Million by 2026 and Grow at 10.3% CAGR in the 2019 to 2026 Timeframe | [180-Pages] Report...

When the decision is made to have a stem cell or bone marrow transplant, there are several steps in theprocess. The steps are much the same, no matter what type of transplant youre going to have.

You will first be evaluated to find out if you are eligible for a transplant. A transplant is very hard on your body. For many people, transplants can mean a cure, but for some people, problems can lead to severe complications or even death. Youll want to weigh the benefits and risks before you start.

Transplants can also be hard emotionally. They often require being in the hospital, being isolated, and theres a high risk of side effects. Many of the effects are short-term, but some problems can go on for years. This can mean changes in the way you live your life. For some people its just for a while, but for others, the changes may be lifelong. Some of the side effects are really unpleasant and can be serious. Your cancer care team will do everything they can to make you comfortable, but some of the side effects may not be completely controlled or relieved.

Before you have a transplant, you need to discuss the transplant process and all its effects with your doctors. It also helps to talk with others who have already had transplants.

Its also very hard going through weeks and months of not knowing how your transplant will turn out. This takes a lot of time and emotional energy from the patient, caregivers, and loved ones. Its very important to have the support of those close to you. For example, youll need a responsible adult who will be with you to give you medicines, help watch for problems, and stay in touch with your transplant team after you go home. Your transplant team will help you and your caregiver learn what you need to know. The team can also help you and your loved ones work through the ups and downs as you prepare for and go through the transplant.

Many different medical tests will be done, and questions will be asked to try to find out how well you can handle the transplant process. These might include:

You will also talk about your health insurance coverage and related costs that you might have to pay.

You may have a central venous catheter (CVC) put into a large vein in your chest. This is most often done as outpatient surgery, and usually only local anesthesia is needed (the place where the catheter goes in is made numb). Nurses will use the catheter to draw blood and give you medicines.

If youre getting an autologous transplant, a special catheter can be placed that can also be used when your stem cells are being removed or harvested.

The CVC will stay in during your treatment and for some time afterward, usually until your transplanted stem cells have engrafted and your blood counts are on a steady climb to normal.

Younger people, people who are in the early stages of disease, or those who have not already had a lot of treatment, often do better with transplants. Some transplant centers set age limits. Some people also may not be eligible for transplant if they have other major health problems, such as serious heart, lung, liver, or kidney disease. A mini-transplant, described under Allogeneic stem cell transplant in Types of Stem Cell Transplants for Cancer Treatment may be an option for some of these people.

The hospitals transplant team will decide if you need to be in the hospital to have your transplant, if it will be done in an outpatient center, or if you will be in the hospital just for parts of it. If you have to be in the hospital, you will probably go in the day before pre-transplant chemo or radiation treatment begins (see the next section), the transplant team makes sure you and your family understand the process and want to go forward with it.

If you will be having all or part of your transplant as an outpatient, youll need to be very near the transplant center during the early stages. Youll need a family member or loved one to be a caregiver who can stay with you all the time. You and the caregiver will also need reliable transportation to and from the clinic. The transplant team will be watching you closely for complications, so expect to be at the clinic every day for a few weeks. You may still need to be in the hospital if your situation changes or if you start having complications.

To reduce the chance of infection during treatment, patients who are in the hospital are put in private rooms that have special air filters. The room may also have a protective barrier to separate it from other rooms and hallways. Some have an air pressure system that makes sure no unclean outside air gets into the room. If youre going to be treated as an outpatient, you will get instructions on avoiding infection. Usually, people who have transplants are in a separate, special part of the hospital to keep as many germs away as possible.

The transplant experience can be overwhelming. Your transplant team will be there to help you prepare for the process physically and emotionally and to discuss your needs. Every effort will be made to answer questions so you and your family fully understand what will be happening to you as you go through transplant.

Its important for you and your family to know what to expect, because once conditioning treatment begins (see the next section), theres no going back there can be serious problems if treatment is stopped at any time during transplant.

Having a transplant takes a serious commitment from you and your caregiver and family, so it is important to know exactly what to expect.

Conditioning, also known as pre-transplant treatment,bone marrow preparation, or myeloablation, is usually treatment with high-dose chemo and/or radiation therapy. Its the first step in the transplant process and typically takes a week or two. Its done for one or more of these reasons:

The conditioning treatment is different for every transplant. Your treatment will be planned based on the type of cancer you have, the type of transplant, and any chemo or radiation therapy youve had in the past.

If chemo is part of your treatment plan, it will be given in your central venous catheter and/or as pills. If radiation therapy is planned, its given to the entire body (called total body irradiation or TBI). TBI may be given in a single treatment session or in divided doses over a few days.

This phase of the transplant can be very uncomfortable because very high treatment doses are used. Chemo and radiation side effects can make you sick, and it may take you months to fully recover. A very common problem is mouth sores that will need to be treated with strong pain medicines. You may also have nausea, vomiting, be unable to eat, lose your hair, and have lung or breathing problems.

Conditioning can also cause premature menopause in women and often makes people sterile (unable to have children). (See Stem Cell Transplant Side Effects.)

After the conditioning treatment, youll be given a couple of days to rest before getting the stem cells. They will be given through your central venous catheter, much like a blood transfusion. If the stem cells were frozen, you might get some drugs before the stem cells are given. These drugs are used to help reduce your risk of reacting to the preservatives that are used when freezing the cells.

If the stem cells were frozen, they are thawed in warm water then given right away. There may be more than 1 bag of stem cells. For allogeneic or syngeneic transplants, the donor cells may be harvested (removed) in an operating room, and then processed in the lab right away. Once they are ready, the cells are brought in and given to you theyre not frozen. The length of time it takes to get all the stem cells depends on how much fluid the stem cells are in.

You will be awake for this process, and it doesnt hurt. This is a big step and often has great meaning for patientsand their families. Many people consider this their rebirth or chance at a second life. They may celebrate this day as they would their actual birthday.

Side effects from the infusion are rare and usually mild. The preserving agent used when freezing the stem cells causes many of the side effects. For instance, you might have a strong taste of garlic or creamed corn in your mouth. Sucking on candy or sipping flavored drinks during and after the infusion can help with the taste. Your body will also smell like this. The smell may bother those around you, but you might not even notice it. The smell, along with the taste, may last for a few days, but slowly fades away. Often having cut up oranges in the room will offset the odor. Patients who have transplants from cells that were not frozen do not have this problem because the cells are not mixed with the preserving agent.

Other side effects you might have during and right after the stem cell infusion include:

Again, side effects are rare and usually mild. If they do happen, they are treated as needed. The stem cell infusion must always be completed.

The recovery stage begins after the stem cell infusion. During this time, you and your family wait for the cells to engraft, or take, after which they start to multiply and make new blood cells. The time it takes to start seeing a steady return to normal blood counts varies depending on the patient and the transplant type, but its usually about 2 to 6 weeks. Youll be in the hospital or visit the transplant center daily for a number of weeks.

During the first couple of weeks youll have low numbers of red and white blood cells and platelets. Right after transplant, when your counts are the lowest, you may be given antibiotics to help keep you from getting infections. You may get a combination of anti-bacterial, anti-fungal, and anti-viral drugs. These are usually given until your white blood cell count reaches a certain level. Still, you can have problems, such as infection from too few white blood cells (neutropenia), or bleeding from too few platelets (thrombocytopenia). Many patients have high fevers and need IV antibiotics to treat serious infections. Transfusions of red blood cells and platelets are often needed until the bone marrow starts working and new blood cells are being made by the infused stem cells.

Except for graft-versus-host disease, which only happens with allogeneic transplants, the side effects from autologous, allogeneic, and syngeneic stem cell transplants are much the same. Problems may include stomach, heart, lung, liver, or kidney problems. (Stem Cell Transplant Side Effects goes into the details.) You might also go through feelings of distress, anxiety, depression, joy, or anger. Adjusting emotionally after the stem cells can be hard because of the length of time you feel ill and isolated from others.

You might feel as if you are on an emotional roller coaster during this time. Support and encouragement from family, friends, and the transplant team are very important to get you through the challenges after transplant.

The discharge process actually begins weeks before your transplant. It starts with the transplant team teaching you and your primary (main) caregiver about:

For the most part, transplant centers dont send patients home until they meet the following criteria:

(Why Are Stem Cell Transplants Used as Cancer Treatment? has more information about neutrophils, platelets, and hematocrit).

If you do not meet all of these requirements, but still dont need the intensive care of the transplant unit, you might be moved to another oncology unit. When you do go home, you might need to stay near the transplant center for some time, depending on your condition.

The process of stem cell transplant doesnt end when you go home. Youll feel tired, and some people have physical or mental health problems in the rehabilitation period. You might still be taking a lot of medicines. These ongoing needs must now be managed at home, so caregiver and friend/family support is very important.

Transplant patients are followed closely during rehab. You might need daily or weekly exams along with things like blood tests, and maybe other tests, too. During early rehab, you also might need blood and platelet transfusions, antibiotics, or other treatments. At first youll need to see your transplant team often, maybe even every day, but youll progress to less frequent visits if things are going well. It can take 6 to 12 months, or even longer, for blood counts to get close to normal and your immune system to work well. During this time, your team will still be closely watching you.

Some problems might show up as much as a year or more after the stem cells were infused. They can include:

Other problems can also come up, such as:

Your transplant team is still there to help you, even though the transplant happened months ago. Its important that you tell them about any problems you are having they can help you get the support you need to manage the changes that you are going through. They can also help you know if problems are serious, or a normal part of recovery. The National Bone Marrow Transplant Link helps patients, caregivers, and families by providing information and support services before, during, and after transplant. They can be reached at 1-800-LINK-BMT (1-800-546-5268) or online at http://www.nbmtlink.org.

Read more:
Getting a Stem Cell or Bone Marrow Transplant - American Cancer Society

A South Korean biotech company says it will use natural killer (NK) cells, exosomes and brown adipose-derived stem cells (ADSC) as treatment of long COVID.

NK cells are a type of immune cell that have granules or small particles that can kill tumor cells or those infected with a virus. Panacell Biotech said they can be used to treat those with terminal illness as well as those with long COVID or post COVID-19 conditions.

The company isSouth Koreasresearch institute specializing in advanced regenerative medical cell therapy using adipose-derived stem cells (ADSC).

It announced today (August10)that it will soon conduct those cells toxicity tests through clinical trials and laboratory animals.

Currently, inSouth Korea, there are guidelines for plasma treatment that administers plasma from patients who have recovered from COVID-19 to other patients. Although there already exist COVID-19 treatments, such as Paxlovid,aclear therapeutic effect has not been confirmed yet.

There are more than 60 long COVID conditions.

According to the Mayo Clinic, one in four people aged 65 or above suffer from aftereffects of COVID-19.

It has been reported that people with long COVID often experience an extremely broad variety of symptoms, including less well-known side effects such as amnesia, and an inability to perform familiar movements or commands.

Panacell said it is believed that about four million people or 2.4% of the U.S. employed population have reduced ability to work because of long COVID.

Associate professor Gwenalle Douaud at the Nuffield Department of Clinical Neurosciences (NDCN),University of Oxford, said her team observed a greater reduction in grey matter thickness and tissue contract in the orbitofrontal cortex and parahippocampal gyrus.

She said: We saw greater changes in markers of tissue damage in regions that are functionally connected to primary olfactory cortex.

While the long-term effects of COVID-19 on smell remaininconclusive, the study suggests a possible connection between brain changes by COVID-19 and memory.

The company says there have been many clinical results in which the coronavirus causes inflammation in various organs, including the respiratory system, and chronic symptoms persist.

Sun Yanrong, deputy director of the China Biotechnology Development Center, said: We are continuing to monitor the treatment using stem cells. InWuhan, over 200 patients have already been treated with stem cells.

The clinical treatment results show that the stem cell therapy has good safety and has also been confirmed to have a therapeutic effect. It was also effective in recovering the lungs.

Seung-Ho Choi, CEO of Panacell Biotech, added: We expect that this clinical trial will reveal therapeutic effects of stem cell therapy along with these treatments.

Panacell Biotech is a bio institute in advanced regenerative medicine and cell therapy, recognized for its contributions to the development of biotechnology by researching stem cell culture and cell banking, focusing on the development of treatments for various cancers and incurable diseases.

Excerpt from:
Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu

Selma Blair reveals how she's changed her approach to beauty and makeup since her 2018 multiple sclerosis diagnosis.

During an interview with InStyle, the 50-year-old actress got candid about her new approach to life and how her chronic disease had inspired her to create a beauty brand after undergoing her medical treatments.

"After I had treatment, I'd honestly, like, stopped looking in the mirror," Blair confessed. "My hair was short, I was bloated, I had alopecia on my lashes and my face. And it was all so much effort I sometimes don't see well so I just stopped, and I didn't think I missed it."

Although the side effects may have kept her from looking in the mirror, the "Legally Blonde" star insists that she never viewed makeup or self-care as "frivolous."

Selma Blair Opens Up About Alleged Assault by Now Ex-Boyfriend That Landed Her in Hospital View Story

Rather, she revealed that beauty, fashion and makeup had always been powerful tools in her self-care kit. Developing products for her brand Guide Beauty that were still accessible to use after the effects of her MS diagnosis became "a real turning point."

"I've never thought of fashion, makeup really, any of our ways of self-care and presenting ourselves as frivolous," she said "It was a real turning point for me, it was like, 'OK, let's start waking up again.'"

Guide Beauty features a collection of makeup and beauty tools that "invite everybody to the table" and are easy to use for people who suffer from MS, chronic diseases or have other disabilities.

"You're not designing for an 'us' or a 'them,'" she explained. "You're just looking to design for that beautiful 'we' moment: When we all get to play in the same world together with makeup."

Back in August 2021, Blair gave an update on her battle with MS during her virtual appearance at Discovery+'s TCA presentation. At the time she revealed that she was "in remission" after she had a stem cell transplant and underwent chemotherapy.

Selma Blair 'Told to Make Plans for Dying' in Incredibly Moving Documentary Trailer View Story

"My prognosis is great. I'm in remission. Stem cell put me in remission," the actress said per PEOPLE. "It took about a year after stem cell [transplant] for the inflammation and lesions to really go down."

"I was reluctant to talk about it because I felt this need to be more healed and more fixed," she added. "I've accrued a lifetime of some baggage in the brain that still needs a little sorting out or accepting. That took me a minute to get to that acceptance. It doesn't look like this for everyone."

"I have really felt unwell and misunderstood for so long that it's just, me," Blair said.

"The Sweetest Thing" actress added that being diagnosed with MS "can be very isolating," but said she was fortunate to have a strong support system.

"People took great care of me. I never really like life. I do now -- strange, huh?" she said. "Just because life's so weird. I was so scared in life. To suddenly start to find an identity and a safety in me, to figure out boundaries, time management and energy. I'm having the time of my life."

Excerpt from:
Selma Blair 'Stopped Looking in the Mirror' After MS Treatments - TooFab

Peer-reviewed publication in Cell Stem Cell unveils a novel differentiation process from Dr. Daleys lab to develop mature immune cells from induced pluripotent stem cells (iPSCs), a potentially disruptive advantage in the development of allogeneic iPSC-derived immunotherapies

New company to leverage ElevateBios unique iPSC platform and ecosystem of enabling technologies and manufacturing capabilities to create allogeneic immune cell therapies

First company to emerge from the previously announced five-year cell and gene therapy collaboration between Boston Childrens Hospital and ElevateBio

WALTHAM, Mass., August 04, 2022--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Childrens Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs). This proprietary differentiation process overcomes the tendency of iPSCs to generate immature, embryonic blood cell types, and enables the generation of multiple subtypes of immune cells that display mature molecular signatures similar to T cells from adult blood. The peer-reviewed publication in the journal Cell Stem Cell showed that iPSC-derived mature T cells exhibited antitumor activity and cytokine secretion and could serve as an ideal source for the development of allogeneic "off-the-shelf" therapies.

This is the first company to emerge from the previously announced five-year collaboration between Boston Childrens Hospital and ElevateBio to accelerate the development of novel cell and gene therapies.

"At ElevateBio, we have been rapidly building fully integrated end-to-end cell and gene therapy enabling technologies and capabilities to enable the worlds most prolific scientific innovators and visionaries, such as Dr. Daley, to push the boundaries of the field and deliver powerful new therapeutic modalities for patients," said David Hallal, Chairman and CEO of ElevateBio. "This exciting new company is the first from our collaboration with Boston Childrens Hospital and is a prime example of how our integrated ecosystem our iPSC cell lines and process development capabilities, our gene editing technology, our CAR and TCR constructs, and our scale-up manufacturing capabilities creates the perfect foundation needed to turn these scientific breakthroughs into transformational medicines."

Story continues

"CAR-T therapies have revolutionized the treatment of certain blood cancers, with complete responses in many patients undergoing this type of treatment. However, current treatment strategies involve manufacturing a customized CAR-T cell product for each individual patient, which is cumbersome and labor-intensive," said Daley, senior author of the newly published Cell Stem Cell paper and whose lab is at Boston Childrens Hospital. "Our science offers an approach to circumvent these hurdles by offering an entirely new way of making allogeneic immune cell therapies that could pave the way for powerful treatments for a wide range of cancers."

Key findings shared in Cell Stem Cell publication: "EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity" (1):

A novel differentiation process discovered in Dr. George Daleys lab at Boston Childrens Hospital has been shown to promote definitive hematopoiesis and supports efficient production of mature T cells

This novel differentiation process incorporates repression of the histone methyltransferase EZH1 during iPSC differentiation to facilitate T cell maturation. The Daley lab showed previously that EZH1 is a negative regulator of lymphoid potential during embryonic blood development.

iPSC-T cells derived in a stroma-free, serum-free system following repression of EZH1, referred to as EZ-T cells, showed a molecular signature more closely resembling mature TCR T cells found in adult blood. Single cell RNA sequencing showed that activated EZ-T cells give rise to high levels of memory T cells, which promotes T cell longevity and may be essential for durable remissions in cancer patients.

In vitro studies showed EZ-T cells engineered to express anti-CD19 Chimeric Antigen Receptors (CARs) exhibited cytotoxic and cytokine-producing effector functions against CD19+ lymphoid tumor cells comparable to CAR-T cells engineered from adult blood.

In a xenograft mouse model injected with CD19+ diffuse large B-cell lymphoma (DLBCL) cells, EZ-T cells expressing anti-CD19 CARs demonstrated increased anti-tumor activity versus traditional iPSC-T cells generated without EZH1 knockdown.

(1) Jing, R., Scarfo, I., Daley, G., EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity, Cell Stem Cell, 2022

About ElevateBio:

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities. Through BaseCamp and its enabling technologies, ElevateBio is focused on growing its collaborations with industry partners while also developing its own portfolio of cellular and genetic medicines. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

For more information, visit us at http://www.elevate.bio, or follow Elevate on LinkedIn , Twitter, or Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005758/en/

Contacts

Investors: Catherine Huchu@elevate.bio

Media: Courtney HeathScientPRCourtney@scientpr.com

Read this article:
ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Childrens Hospital to Develop iPSC-Derived Allogeneic...

Africa July 2022. Currently, umbilical cord blood stem cells are being used to treat blood cancers, inherited blood disorders, and certain metabolic and immune disorders. These diseases are prominent in South Africa, yet access to cord blood stem cells is limited.

Dr. Yvonne Holt is Chief Medical Officer of Netcells Stem Cell Bank the largest established private umbilical cord blood bank in Africa. Dr. Holt acknowledges that great strides have been made internationally with regard to cord blood banking and stem cell treatment. However, its use is still not fully accessible in South Africa.

July is Cord Blood Awareness Month. The company aims to educate the public regarding the importance of umbilical cord blood storage and how it can save lives.

Dr. Holt explains that having access to cord blood provides an important source of stem cells, which can treat many life-threatening illnesses such as blood disorders such as Thalassaemia, sickle cell anemia, aplastic anemia; cancers such as leukemia, lymphoma, and solid tumors of childhood; metabolic and immune disorders.

The umbilical cord blood stem cells are mainly haematopoietic (blood-forming) stem cells. They are therefore used in these illnesses to create new, healthy bone marrow after chemotherapy.

Internationally, cord blood stem cells can be sourced from public banks that collect cord blood from voluntary donations. Since we dont have a local public stem cell bank in South Africa, it puts South African patients at a greater disadvantage, as bringing in cord blood units from overseas is prohibitively expensive.

In the past, the costs associated with private stem cell banking has posed a barrier. However, the launch of Netcells Community Stem Cell Bank in partnership with the South African Bone Marrow Registry (SABMR) the only bank of its kind in the country offers parents the opportunity to store their babys cord blood at a significantly reduced rate.

The cord blood unit can then be used by the family themselves. Alternatively, it can be used by someone else in the community who may need a lifesaving transplant. If the cord blood unit is utilized by someone else, then all costs associated with the storage are refunded to the family.

This will greatly improve transplant options for SAs diverse demographic, as it can be difficult to find a bone marrow stem cell match for patients of African origin given the lack of donors from these communities.

Its important to educate all South Africans regarding the importance of building a donor base that can serve all members of our community, says Dr Holt.

Alternatively, parents can choose to go the private cord blood banking route. They will pay the full price to have their babys cord unit stored exclusively for their child or familys use.

Dr. Holt says the process of collecting blood from a newborns umbilical cord, is easy and painless.

Once collected, it is tested, frozen, and stored in the cord blood bank.

Cord blood stem cells are used to replace dysfunctional blood-producing cells in bone marrow with healthy new cells. Once diseased cells are destroyed by chemotherapy and irradiation, new stem cells are transplanted into the patient to restore normal functioning of the bone marrow.

Netcells also runs a sibling cord blood donor program, called Families of Hope. It aims to improve poor and disadvantaged families access to stem cell banking. This is especially important if they have a child with a stem cell-treatable disease.

If a disadvantaged child requires a bone marrow stem cell transplant, and their mother is expecting a child from the same father, we will facilitate the collection of the cord blood, process, test and store the cord blood until it is needed for transplant in the ill sibling.

In this way, we hope to expand the opportunity to families who are faced with a life-threatening disease but cannot afford to save their babys precious stem cells at birth, she says.

The first cord blood transplant was done in the late 80s. Since then, there have been remarkable advances. In fact, there have been more than 40 000 cord blood transplants done worldwide.

Cord blood stem cells are also proving useful in new areas of regenerative medicine to potentially treat cerebral palsy, autism, and Type 1 diabetes. If the potential of stem cell research is realised, it could lead to breakthroughs in treatments for many diseases we face today.

Researchers are also continuing to look for ways to improve transplant success and toincrease the number of stem cellscollected from each cord, which could potentially reduce the costs associated with cord blood transplants in the future.

Cord blood is by no means regarded as a miracle cure. However, it provides an important source of stem cells to treat several life-threatening illnesses. It also has the potential to treat many more common diseases in the future as technology progresses.

For now, collecting your babys stem cells remains a valuable insurance policy for you and your loved ones.

For more info regarding cord blood banking, visit Next Biosciences.

Dr. Yvonne Holt

Yvonne Holt graduated from the University of the Witwatersrand in 1997 with a Bachelor in Medicine and Surgery (MBBCH Wits). Dr. Holt worked as a Medical Officer in the departments of Paediatrics and Obstetrics and Gynaecology for 4 years after graduation. She obtained a Diploma in Child Health (DCH) during this time.

In 2006, Dr. Holts interest in the fields of Obstetrics and Gynaecology, Paediatrics, and stem cell technology brought her to a new career path. She joined Next Biosciences as Medical Director.

In this capacity, Yvonne is responsible for the medical development of the stem cell program at Next Biosciences. She also highlights the benefits of this new technology. In 2011, Yvonne completed a 2 year, internationally recognized Diploma in Transfusion Medicine through the University of Bloemfontein.

See original here:
Stem Cells Are Needed To Treat Life-Threatening Diseases - Longevity LIVE - Longevity LIVE

A stem cell hair transplant is similar to a traditional hair transplant. But rather than removing a large number of hairs to transplant to the area of hair loss, a stem cell hair transplant removes a small skin sample from which hair follicles are harvested.

The follicles are then replicated in a lab and implanted back into the scalp in the areas of hair loss. This allows hair to grow where the follicles were taken from, as well as where theyre transplanted.

Stem cell hair transplants exist only in theory at the moment. Research is ongoing. Its estimated that stem cell hair transplants may be available by 2020.

Stem cells are cells that have the potential to develop into different types of cells found in the body. Theyre unspecialized cells that are unable to do specific things in the body.

However, theyre able to divide and renew themselves to either stay stem cells or become other types of cells. They help repair certain tissues in the body by dividing and replacing damaged tissues.

A stem cell hair transplant was successfully performed by Italian researchers in 2017.

The procedure begins with a punch biopsy to extract stem cells from the person. The punch biopsy is performed using an instrument with a circular blade thats rotated into the skin to remove a cylindrical sample of tissue.

The stem cells are then separated from the tissue in a special machine called a centrifuge. It leaves a cell suspension thats then injected back into the scalp in the areas of hair loss.

There are several different research teams working on stem cell hair loss treatments. While the procedures may vary slightly, theyre all based on growing new hair follicles in a lab using a small skin sample from the patient.

Currently, there are some clinics offering a version of stem cell hair transplants to the public. These arent approved by the U.S. Food and Drug Administration (FDA). Theyre considered investigational.

In 2017, the FDA released a warning about stem cell therapies. The warning advises anyone considering stem cell therapies to choose those that are either approved by the FDA or being studied under an Investigational New Drug Application (IND). The FDA authorizes INDs.

These procedures are performed in-office on an outpatient basis. They entail removing fat cells from the persons abdomen or hip using a liposuction procedure under local anesthesia.

A special process is used to remove the stem cells from the fat so that they can be injected into the scalp. This procedure takes approximately 3 hours.

The clinics that currently offer this procedure cant provide a guarantee for the outcome of the procedure. The results, if any, can vary from person to person. It may require several treatments over many months to see results.

Some research has found stem cell hair transplants can be effective in treating different hair loss conditions, including:

Some pain following the procedure is expected. It should subside within a week.

No recovery time is required, though excessive exercise should be avoided for a week. Some scarring can be expected where the fat has been removed.

You wont be able to drive yourself home following the procedure because of the effects of the local anesthesia.

Theres very little information available about the possible side effects of stem cell hair transplants. As with any medical procedure, theres always the risk of bleeding or infection at the site of the sample and the injection. Scarring is also possible.

Though complications from a punch biopsy are rare, theres a small risk of damage to the nerves or arteries beneath the site. Liposuction can also cause the same side effects and complications.

The research available on the success rate of stem cell hair transplants is very promising. The results of the Italian study showed a 29 percent increase in hair density 23 weeks after the last treatment.

The clinics that currently offer stem cell hair therapies not approved by the FDA dont make any guarantees in regard to results or success rates.

The cost of stem cell hair transplants hasnt been determined since theyre still in the research stages.

Some of the investigational stem cell hair replacement therapies being offered by various clinics range from approximately $3,000 to $10,000. Final cost depends on the type and extent of the hair loss being treated.

The stem cell hair transplant treatments being researched are expected to be available to the public by 2020. Stem cell hair transplants offer options to people who arent candidates for the hair loss treatments currently available.

While some clinics are offering stem cell hair replacement therapies, these are considered investigational and havent been approved by the FDA.

Read the original here:
Stem Cell Hair Transplant: What Is It and When Will It Be Available?

What are stem cells?

Our bodies are made up of about 200 different types of cells, such as muscle cells, skin cells and nerve cells. Each cell type performs a specialised function. Stem cells are cells that are not specialised. Their role is to replace specialised cells that have been lost through injury, diseases, or the normal course of events.

Medical research into stem cells is still at the very early stages. Our understanding of the risks associated with stem cell treatment is limited. Further research is required to create safe and effective treatments.

Are stem cell treatments safe and effective?

In Australia, the only proven safe and effective stem cell treatment is haematopoietic stem cell transplantation (using stem cells from umbilical cord blood or bone marrow) for the treatment of disorders of the blood and immune system such as leukaemia.

Currently, no other stem cell treatment has been demonstrated to be safe and effective. However, some clinics located both in Australia and overseas offer unproven stem cell treatments.

Any unproven stem cell treatment may be unsafe, posing serious risks to your health. The risks include infection, allergic reactions or the development of cancer; complications that can be fatal.

What stem cell treatments are approved by the TGA?

The only established stem cell treatment approved in Australia is haematopoietic stem cell (HPC) transplantation (using stem cells from umbilical cord blood or bone marrow), which is standard practice for the treatment of disorders of the blood and immune system such as leukaemia. The use of fresh bone marrow-derived HPC is standard practice and is exempt from oversight by TGA. Cord-blood derived HPC is usually stored frozen prior to use, so involves some processing, and is approved by TGA.

What are the risks of undergoing unproven stem cell treatments?

An unproven stem cell treatment may also pose serious, potentially fatal, risks to your health including infection, allergic reactions, rejection of the cells by your immune system and the development of cancer.

Unproven stem cell treatments may cause financial hardship, including treatment and ongoing follow-up costs, as well as the cost of emergency medical care in the event that something goes wrong. If you undergo treatment outside Australia, there are additional costs associated with travel.

Importantly, undergoing an unproven stem cell treatment may interfere with proven and potentially beneficial therapies recommended by your general practitioner or specialist. It can also disqualify you from participation in a registered clinical trial.

Does the TGA regulate stem cell treatments?

In Australia, the Therapeutic Goods Administration (TGA) is responsible for the regulation of products for therapeutic use including human cells and tissues (termed 'biologicals'). This includes human stem cell treatments.

However, the TGA does not regulate medical practice. Some products that would otherwise be considered biologicals are excluded from TGA regulation (through the Therapeutic Goods (Excluded Goods) Determination 2018). Under this provision stem cell treatments may not be subject to regulation by TGA if they meet all of the following criteria:

Where one or more criteria are not met, including advertising to consumers, regulation by TGA will apply.

Are there any approved facilities for storing stem cells in Australia?

Cord blood can be stored in Australia. There are approved facilities for storing cord blood stem cells (collected from a newborn's umbilical cord). There are currently no TGA approved facilities for the storage of other stem cells in Australia.

Does the TGA regulate dental pulp stem cells?

Stem cells derived from sources such as dental pulp are subject to the same regulatory requirements as all other human cell and tissue products for therapeutic use.

However, the use of these stem cells to produce a product that could be of therapeutic use is only in the research and development stage. It is possible that in coming years these stem cells will be used in products for clinical trials, but products suitable for full marketing approval by the TGA are still some time away.

What are autologous stem cells?

Autologous cells are those that are removed from, and applied to, the same person, so the donor and recipient are the same.

Is it safe to use autologous stem cells?

Autologous cells are those that are removed from and applied to the same person. These cells may be treated, processed or purified after removal. As the cells come from the same person, there is a lower chance of reaction and rejection of the cells by the patient's immune system.

However, an unproven autologous stem cell treatment may be unsafe, posing serious risks to your health. The risks include infection and growth of specialised tissue in the wrong place (ectopic tissue formation).

Unproven stem cell treatments may also involve significant financial costs, including treatment and follow-up costs, as well as the cost of emergency medical care in the event that something goes wrong. Undergoing an unproven stem cell treatment may interfere with proven and potentially beneficial therapies or treatment plans recommended by your general practitioner or specialist. It can also disqualify you from participation in a registered clinical trial.

Can I use Cord Blood stem cells from my own pregnancy for my own treatment?

The collection and use of cord blood stem cells for a specific patient is known as directed donation. On rare occasions, a hospital will collect and store a baby's cord blood for a family member who has a medical condition that can be treated with cord blood transplantation. This requires a treating doctor's approval.

Should I use a natural therapy that claims to increase stem cells that is not approved by the TGA or available via the Special Access Scheme?

The TGA ensures that where specific therapeutic claims are made about a product or therapy then these are supported and the product is safe. For natural therapies that do not have oversight by TGA there is no guarantee of safety or effective use.

More:
Stem cell treatments and regulation - a quick guide for consumers

NEW YORK--(BUSINESS WIRE)--The Tisch Multiple Sclerosis Research Center of New York, the worlds largest independent research center focusing on MS, is proud to announce that its FDA-approved stem cell treatment study was featured in an article in BioSpace.

Preliminary analysis of the study results found that stem cell treatments substantially improved muscle strength and disability scores, particularly among patients with lower levels of disability. Interviewing Dr. Saud A. Sadiq, the Director and Chief Research Scientist of the Tisch MSRCNY, as well as Senior Research Scientist Dr. Violaine Harris, the article features the progress and key results of the stem cell treatment study, as well as the broader history and goals of the center.

We are excited to share more about our stem cell treatment research, which is a key study in service of our centers overarching goal of finding the cause of and the cure for MS, said Dr. Sadiq. Furthermore, the study has enormous potential not only for the treatment of MS patients, but also promising potential implications for those with other neurodegenerative diseases. Were delighted to share our analysis with the broader public and scientific community, and look forward to sharing further updates on this groundbreaking research as it progresses.

The full BioSpace article can be accessed here.

About the Tisch MS Research Center of New York

The mission of the Tisch Multiple Sclerosis Research Center of New York is to conduct groundbreaking medical research to ensure unparalleled care and positive outcomes for MS patients. Its integrated relationship with the International Multiple Sclerosis Management Practice (IMSMP) accelerates the pace at which research discoveries translate from lab bench to bedside. The Center aims to identify the cause of MS, understand disease mechanisms, optimize therapies, and repair the damage caused by MS while offering patients access to the best and most advanced treatments possible.

Visit link:
Tisch Multiple Sclerosis Research Center of New York Study Featured in BioSpace - Business Wire

MATFORS, Sweden, June 21, 2022 (GLOBE NEWSWIRE) -- Sweden-based NorthX Biologics (NorthX) is expanding into cell therapy manufacturing at its existing GMP-facility, as well as in premises at the Karolinska University Hospital campus in Stockholm. This initiative is part of NorthXs Innovation Hub, an Innovation Track designed to provide development and GMP-manufacturing services to the next generation of drug development companies and innovative research groups in need of NorthXs Good Manufacturing Practice (GMP) expertise.

NorthX has one of Northern Europes largest clinical-grade manufacturing capacities for plasmid DNA, recombinant proteins, cell banking and associated gene therapy services and this expansion into cell therapy is a major step to complete our offering for innovative clients. We are especially excited to work with Dr. Kristian Tryggvason, a leader in cell therapy technologies, and his team, said Dr. Ted Fjllman, CEO of NorthX.

After having built up BioLamina and its cell culture reagents that are used worldwide both in academia and industry, Dr. Tryggvason recently launched his latest venture: Alder Therapeutics. In addition to its own product development, the company now entered into an agreement to help NorthX expand its cell culture services to many new different cell types, including pluripotent stem cells. The Alder team will also help to design and validate NorthXs new process development and GMP-manufacturing labs in Matfors, alongside those being established at the Karolinska University Hospital campus in Stockholm.

Our goal is to be able to offer synergies to both cell and gene therapy clients and to collaborate with them through our Innovation Track, in which we work hand in hand with our clients regarding process development, manufacturing, and analytics to progress clinical programs and bring life-saving treatments to patients, added Aaron Small, NorthX VP of Global Sales and Corporate Development

Universities and cell therapy companies worldwide need GMP-grade development and manufacturing capacity, as it is complex and outside the scope of most biotech companies to build themselves. NorthX Biologics is already helping to translate cutting-edge gene therapy research into clinical development and now we will together build upon the existing broad cell therapy know-how in Sweden to do the same for cell therapies, said Dr. Kristian Tryggvason, CEO Alder Therapeutics.

About NorthX Biologics:

NorthX Biologics provides process development and manufacturing services with expertise in plasmids, proteins and other advanced biologics. NorthX Biologics sits in the heart of Sweden, and the team has been manufacturing biologics to GMP since 1988. In 2021 NorthX was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies. For more information see http://www.nxbio.com

About Alder Therapeutics:

Headquartered inStockholm, Alder Therapeutics AB is a novel development stage, cell therapy platform company aiming to develop and manufacture the best functional cell therapy products based on the most simple and robust processes. Alder Therapeutics unique cell therapy platform will allow manufacturing of better cells at a lower cost, which will make pluripotent cell therapy treatment available for ever more patients. Alder Therapeutics will play an important role in opening the next era in medicinal treatment. For more information and important updates, please visit. http://www.aldertx.com

For further information please email NorthX at:contact@nxbio.com

Originally posted here:
NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - GlobeNewswire